1243 results
Publication
Sales at end september 2025
9-month sales: €384 million (-1.3% at constant exchange rates and -3.5% on a reported basis) 9-month sales of Essential products: €244 million (64% of sales, +2.7% at constant exchange rates and +1.1% on a reported basis)
Publication
Monthly information regarding the total number of voting rights – September 2025
As per articles L233‐8‐II of « Code de Commerce » and 223.16 of the «Reglement Général de L’Autorité des Marchés Financiers »
Basic page
FAQ Phovia®
Is it okay to use post-surgical on orthopaedics who have had surgical implants? Yes it can be used on post-surgical patient with implants including plates, screws and pins. Red light laser is not used for approx. 24 hours after surgery as it can increase blood flow therefore excessive bleeding. Is...
News
2025 half-year Results
Sales: €258m (-1.0% at constant exchange rates) Essential products sales: €165m (+4.2% at constant )exchange rates Net income, Group share: €25m (9.7% of sales) EBITDA: €53m (20.4% of sales) Cash flow generation: €51m The Board of Directors of Vetoquinol SA, meeting on September 9, 2025, approved...
Publication
2025 Half-Year Results
Sales: €258m (-1.0% at constant exchange rates) Essential products sales: €165m (+4.2% at constant exchange rates) Net income, Group share: €25m (9.7% of sales) EBITDA: €53m (20.4% of sales) Cash flow generation: €51m
Publication
2025 Half-Year Results
Contents: 01. Activity for the first half of 2025 02. Consolidated results for the first half of 2025 03. Strategy and outlook
Publication
Monthly information regarding the total number of voting rights – August 2025
As per articles L233‐8‐II of « Code de Commerce » and 223.16 of the «Reglement Général de L’Autorité des Marchés Financiers »